Keystone Labs Keeps OTC Drugs In Plans After Court Orders Manufacturing Halt
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Keystone Labs agrees to cease manufacturing OTC drugs after repeat GMP violations following a 2013 FDA warning letter, including failure to investigate sources of contamination. Firm says it informed FDA it would outsource OTC product manufacturing and continue making hair and skin care cosmetic formulas.
You may also be interested in...
OTC Private Labeler RIJ Pharmaceutical Must 'Fully Remediate' Water System
FDA asks RIJ Pharmaceutical, which recalled a dozen products last year, to provide plans for developing a solid water system design and mixing process. It warns private label manufacturer about contaminated, "‘super-potency" OTC drugs that resulted from GMP violations.
FDA Consumer Health Product Recalls For May 4-25, 2016
Recalls reported by FDA for OTC drugs, nutritionals and personal care products.
In Brief
New studies from Chanel researchers and Gettysburg College support makeup’s anti-aging effect. More news in brief.